The effect of acute ingestion of a large dose of alcohol on the hemostatic system and its circadian variation.
OBJECTIVE
Heavy binge drinking may trigger the onset of embolic stroke and acute myocardial infarction, but the underlying mechanisms are unclear. The effects of binge drinking on the hemostatic system and its circadian variation have not been investigated. We investigated the effects of an acute intake of a large dose of alcohol (1.5 g/kg).


METHODS
Twelve healthy, nonsmoking men participated in sessions where they were served ethanol in fruit juice or served fruit juice alone and, lying in a supine position, were followed up for 12 to 24 hours. The treatments were randomized and separated from each other by a 1-week washout period. Blood and urine were collected for hemostatic measurements.


RESULTS
The urinary excretion of the platelet thromboxane A(2) metabolite 2, 3-dinor-thromboxane B(2) was significantly (P<0.05) greater during the night after an evening intake of alcohol than during the control night. A smaller increase was observed during the daytime after an intake of alcohol in the morning. The effects on the endothelial prostacyclin metabolite 2,3-dinor-6-ketoprostaglandin F(1alpha) excretion were negligible. A 7-fold increase in plasminogen activator inhibitor 1 activity was observed after both morning (P<0. 05) and evening (P<0.01) intakes of alcohol.


CONCLUSIONS
This is the first study to suggest that acute ingestion of a relatively large but tolerable dose of alcohol transiently enhances thromboxane-mediated platelet activation. The observations also demonstrate alcohol-induced changes in the normal circadian periodicity of the hemostatic system in subjects not accustomed to consumption of alcohol.
Numminen
H
H
Department of Neurology, Oulu University Hospital, Finland.
Syrjälä
M
M
Benthin
G
G
Kaste
M
M
Hillbom
M
M
D015121:6-Ketoprostaglandin F1 alpha / Q000031:analogs & derivatives / Q000652:urine; D000208:Acute Disease; D000328:Adult; D000435:Alcoholic Intoxication / Q000097:blood*; D015415:Biomarkers; D002940:Circadian Rhythm / Q000187:drug effects*; D003404:Creatinine / Q000652:urine; D018592:Cross-Over Studies; D004198:Disease Susceptibility; D004334:Drug Administration Schedule; D000431:Ethanol / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D005342:Fibrinolysis / Q000187:drug effects; D018056:Hemorheology / Q000187:drug effects; D006487:Hemostasis / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000097:blood / Q000453:epidemiology; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis; D015539:Platelet Activation / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects; D020521:Stroke / Q000097:blood / Q000453:epidemiology; D016683:Supine Position; D013929:Thromboxane B2 / Q000031:analogs & derivatives / Q000652:urine
D015415:Biomarkers; D017395:Plasminogen Activator Inhibitor 1; D000431:Ethanol; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C028965:2,3-dinor-thromboxane B2; C028290:2,3-dinor-6-ketoprostaglandin F1alpha; D003404:Creatinine